Research Use Only
This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
Retatrutide
Metabolic & Weight LossPhase 3Also known as: Reta, RC-3R, PEP-3R, GLP-R, GIP/GLP/Glucagon, Triple Agonist, GLP-3 RT, GLP-3
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials demonstrated unprecedented 24.2% mean body weight reduction at 48 weeks with 12 mg weekly dosing — the largest weight loss ever reported for an anti-obesity drug in a clinical trial.
Overview
Key Takeaways
- →Extreme weight loss
- →Metabolic syndrome
- →Appetite control
- →Half-life: ~6 days
At A Glance
Retatrutide activates three metabolically critical receptors: GLP-1R drives appetite suppression and insulin secretion; GIPR modulates lipid metabolism and adipose tissue function; and glucagon receptor agonism uniquely increases hepatic energy expenditure, promotes fat oxidation, and stimulates thermogenesis. The glucagon component is the key differentiator — it drives additional caloric expenditure that single and dual agonists cannot achieve. This triple mechanism produces compounding metabolic effects across appetite, insulin signaling, and energy output.
Retatrutide activates three metabolically critical receptors: GLP-1R drives appetite suppression and insulin secretion; GIPR modulates lipid metabolism and adipose tissue function; and glucagon receptor agonism uniquely increases hepatic energy expenditure, promotes fat oxidation, and stimulates thermogenesis. The glucagon component is the key differentiator — it drives additional caloric expenditure that single and dual agonists cannot achieve. This triple mechanism produces compounding metabolic effects across appetite, insulin signaling, and energy output.
Overview
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials demonstrated unprecedented 24.2% mean body weight reduction at 48 weeks with 12 mg weekly dosing — the largest weight loss ever reported for an anti-obesity drug in a clinical trial. Currently in Phase 3 TRIUMPH trials.
Potential Benefits
Potential Research Fields
Chemical Information
IUPAC Name
Not fully disclosed (Eli Lilly proprietary)
CAS Number
2381294-46-4
Molecular Formula
C223H343F3N46O70
Molecular Mass
4845.44 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction Matrix
Contraindications
Personal or family history of MTC. MEN 2. Pancreatitis history. Severe GI disease. Pregnancy or breastfeeding. Type 1 diabetes.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$119.99
$11.9990
3
3
vial
Related Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
Cagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).
Research Score
129 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~6 days
Molecular Weight
4845.44 g/mol
Administration
Subcutaneous
CAS Number
2381294-46-4
Trial Phase
Phase 3
Safety Profile
Moderate RiskCommon Side Effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Constipation
- • Decreased appetite
Stop Use If
- Phase 3 trials ongoing — long-term safety profile still being established
- Thyroid tumor history
- Severe GI events
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Retatrutide used for in research?
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials demonstrated unprecedented 24.2% mean body weight reduction at 48 weeks with 12 mg weekly dosing — the largest weight loss ever reported for an anti-obesity drug in a clinical trial. Currently in Phase 3 TRIUMPH trials.
What forms does Retatrutide come in?
Retatrutide is available in vial form.
How much does Retatrutide cost?
Prices start at $119.99 across 3 verified vendors.
How do I compare Retatrutide vendors?
Compare prices, payment methods, shipping, and COA scores across 3 vendors.
Research Tools
Related Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
Cagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).